Compounds > imidazol-1-ylacetic acid
Page last updated: 2024-12-09

imidazol-1-ylacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

imidazol-1-ylacetic acid : An imidazolyl carboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by an imidazol-1-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID656129
CHEMBL ID297390
CHEBI ID70801
SCHEMBL ID77978

Synonyms (65)

Synonym
HMS1684C18
AC-20545
BB 0240486
MLS000074022
imidazol-1-yl-acetic acid
EC-000.1971
22884-10-2
smr000013538
STK260846
1h-imidazol-1-ylacetic acid ,
1-imidazolylacetic acid
I0670
1-(carboxymethyl)imidazole
2-(1-imidazolyl)acetic acid
1-imidazoleacetic acid
chebi:70801 ,
CHEMBL297390 ,
2-(3h-imidazol-4-yl)acetic acid
qafbdrsxxhexgb-uhfffaoysa-
inchi=1/c5h6n2o2/c8-5(9)3-7-2-1-6-4-7/h1-2,4h,3h2,(h,8,9)
2-imidazol-1-ylacetic acid
AKOS000137844
A24846
BBL001468
2-(1h-imidazol-1-yl)acetic acid
1h-imidazole-1-acetic acid
imidazol-1-yl acetic acid
HMS2349E08
FT-0670304
BP-11530
FT-0638263
imidazole-1-acetic acid
whc1j1g932 ,
unii-whc1j1g932
AM20090233
(1-imidazolyl)acetic acid
AB09874
AB00419076-07
imidazol-1-ylacetic acid
2-(imidazol-1-yl)acetic acid
zoledronic acid monohydrate impurity d [ep impurity]
SCHEMBL77978
AB00419076-09
[1h-imidazol-1-yl]acetic acid
2-(n-imidazolyl)acetic acid
QAFBDRSXXHEXGB-UHFFFAOYSA-N
1h-imidazole-1-ylacetic acid
(1h-imidazol-1-yl)acetic acid
SY003214
mfcd01721800
RS-0402
CS-W011164
DTXSID20177425
F8881-7832
J-521520
1h-imidazol-1-ylacetic acid, aldrichcpr
bdbm50026406
Z57396183
J-014887
Q27139105
2-(1h-imidazol-1-yl)aceticacid
imidazole-1-yl-acetic acid
HY-W010448
imidazol-1-yl-essigsaeure, 1h-imidazole-1-acetic acid, imidazole-1-acetic acid
EN300-57904
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
imidazolyl carboxylic acidAny member of the class of imidazoles in which the imidazole ring is substituted by one (or more) carboxy group(s).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency100.00000.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
importin subunit beta-1 isoform 1Homo sapiens (human)Potency7.30785.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency7.30785.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency7.30785.804816.996225.9290AID540253
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium- and chloride-dependent GABA transporter 2Mus musculus (house mouse)IC50 (µMol)199.52601.41255.26838.1283AID595474
Sodium- and chloride-dependent GABA transporter 3Mus musculus (house mouse)IC50 (µMol)42.65791.54883.67618.1283AID595475
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID595477Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595476Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595509Selectivity ratio of pIC50 for mouse GAT3 topIC50 for mouse GAT12011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595475Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595474Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595482Selectivity ratio of pIC50 for mouse GAT3 to pIC50 for mouse GAT22011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595483Selectivity ratio of pIC50 for mouse GAT3 to pIC50 for mouse GAT42011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's6 (66.67)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.10 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		2.0610amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
5-aminovaleric acid
5-aminovaleric acid: from red fox anal secretion; RN given refers to parent cpd. 5-aminopentanoic acid : A delta-amino acid comprising pentanoic acid with an amino substituent at C-5; a methylene homologue of gamma-aminobutyric acid (GABA) that is a weak GABA agonist.		2.0610amino acid zwitterion;
delta-amino acid;
omega-amino fatty acid		human metabolite
beta-alanine
[no description available]		2.0610amino acid zwitterion;
beta-amino acid		agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter
aminocaproic acid
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.		2.0610amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
glycine
[no description available]		2.0610alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
omega-aminoenantic acid
[no description available]		2.0610medium-chain fatty acid
5-imidazolepropionic acid
5-imidazolepropionic acid: competitive inhibitor of urocanase reaction which catalyzes conversion of urocanate into imidazolone propionate; structure. dihydrourocanic acid : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 3 has been replaced by an imidazol-4-yl group.		2.0610imidazoles;
monocarboxylic acid
imidazoleacetic acid
imidazoleacetic acid: RN given refers to cpd without specific location of acetic acid attachment identified; structure. imidazol-5-ylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by an imidazol-5-yl group.. imidazol-4-ylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by an imidazol-4-yl group.		2.0610imidazoles;
monocarboxylic acid		metabolite;
mouse metabolite
5-benzimidazolecarboxylic acid
5-benzimidazolecarboxylic acid: structure in first source		2.0610
urocanic acid
Urocanic Acid: 4-Imidazoleacrylic acid.. urocanic acid : An alpha,beta-unsaturated monocarboxylic acid that is prop-2-enoic acid substituted by a 1H-imidazol-4-yl group at position 3. It is a metabolite of hidtidine.. trans-urocanic acid : A urocanic acid in which the double bond of the carboxyethene moiety has E configuration.		2.0610urocanic acidhuman metabolite
3-(1H-imidazol-1-yl)propanoic acid
[no description available]		2.0610imidazolyl carboxylic acidhuman urinary metabolite
snap 5114
[no description available]		2.0610
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610